Humacyte, Inc. (NASDAQ:HUMA) Short Interest Update

Humacyte, Inc. (NASDAQ:HUMA) saw a large growth in short interest in the month of June. As of June 30th, there was short interest totalling 8,250,000 shares, a growth of 58.7% from the June 15th total of 5,200,000 shares. Approximately 9.0% of the shares of the company are sold short. Based on an average daily volume of 2,760,000 shares, the short-interest ratio is presently 3.0 days.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on HUMA shares. Cantor Fitzgerald restated an “overweight” rating and issued a $7.00 price objective on shares of Humacyte in a research note on Tuesday, July 2nd. Benchmark reiterated a “buy” rating and set a $15.00 price target on shares of Humacyte in a research report on Tuesday, July 2nd. Finally, Piper Sandler reiterated a “neutral” rating and set a $4.00 price target on shares of Humacyte in a research report on Tuesday, March 26th.

Humacyte Trading Up 8.4 %

Shares of HUMA opened at $6.99 on Monday. The business’s 50-day moving average price is $6.23 and its 200-day moving average price is $4.38. Humacyte has a twelve month low of $1.96 and a twelve month high of $9.97. The stock has a market cap of $832.37 million, a PE ratio of -6.99 and a beta of 1.51. The company has a quick ratio of 8.37, a current ratio of 8.37 and a debt-to-equity ratio of 0.61.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings results on Friday, May 10th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.06). On average, equities analysts forecast that Humacyte will post -0.95 EPS for the current fiscal year.

Insider Transactions at Humacyte

In other news, Director Brady W. Dougan sold 271,518 shares of Humacyte stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $7.30, for a total transaction of $1,982,081.40. Following the sale, the director now directly owns 4,559,140 shares in the company, valued at approximately $33,281,722. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Brady W. Dougan sold 271,518 shares of the business’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $7.30, for a total value of $1,982,081.40. Following the sale, the director now directly owns 4,559,140 shares in the company, valued at approximately $33,281,722. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Laura E. Niklason sold 358,630 shares of the business’s stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $7.08, for a total value of $2,539,100.40. Following the completion of the sale, the chief executive officer now owns 4,830,658 shares in the company, valued at $34,201,058.64. The disclosure for this sale can be found here. In the last ninety days, insiders have acquired 54,412 shares of company stock worth $369,107 and have sold 1,628,820 shares worth $12,464,121. Company insiders own 23.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of HUMA. Tower Research Capital LLC TRC grew its holdings in shares of Humacyte by 261.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,989 shares of the company’s stock worth $26,000 after purchasing an additional 6,504 shares in the last quarter. Whittier Trust Co. of Nevada Inc. purchased a new position in shares of Humacyte during the fourth quarter worth about $28,000. Victory Capital Management Inc. purchased a new position in shares of Humacyte during the fourth quarter worth about $29,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Humacyte by 350.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,986 shares of the company’s stock worth $34,000 after purchasing an additional 9,325 shares in the last quarter. Finally, Kovitz Investment Group Partners LLC purchased a new position in shares of Humacyte during the fourth quarter worth about $35,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.